new spin-off of the University of Barcelona: Endoasic Technologies, SL.
development and marketing of chips integrated in endoscopic capsules that can replace the gastrointestinal endoscopy.
Barcelona, March of 2013– last Tuesday, March 19 was Endoasic Technologies, SL, a spin-off of the University of Barcelona (UB) created to develop and market chips to be integrated in endoscopic diagnosis and clinical screening for gastrointestinal cancer capsules.
This technological company driven by the UB, has been created to develop – in the next 2 years – chips EndoD and EndoS will be incorporated capsule endoscopic diagnosis and clinical screening for gastrointestinal cancer, so the current gastrointestinal endoscopy may be substituted for ingestion of this capsule, giving a It improves qualitative patient when you have to do this kind of testing.
Currently there is no other similar chip on the market. In 2009, only in the United States, these endoscopy market was 227 million dollars. Capsules incorporating chips of Endoasic Technologies, will lead to the market the ability to scan active and intuitive, with a comparable to classical endoscopy cost.
The entrepreneurial new spin-off of the UB team is composed of Angel Dieguez, senior lecturer in the Department of electronics of the UB and head of microelectronic design group; Anna Maria Vilà , Professor of the Department of electronics of the UB and expert in the field of microelectronics technology and devices; and Oscar Alonso, researcher in the Group of Dr. Diéguez, PhD in the UB with a thesis in the field of capsule endoscopy for therapy in the digestive tract. The Group has worked for 15 years in the development of integrated circuits for different specific applications, including especially microrobots and endoscopic capsules.
Project Endoasic Technologies has been accompanied by the Foundation Bosch i Gimpera Foundation during the past two years in the definition of its business plan, which was the second prize winner Bioemprendedor 21st 2011 – promoted by Biocat, la Caixa, the Chamber of Commerce, genome Spain and Barcelona Activa – , as well as in the negotiation of the contract of transfer of technology.
from left to right: M. Carme Verdaguer, Director general FBG and representative of CIC-UB; Anna Maria Vilà , Angel Dieguez and Oscar Alonso, entrepreneurial team members.
la Universidad de Barcelona enters the shareholders of its spin-off through innovative and scientific culture (CIC-UB), the management company of the UB Group stakes in the UB spinoff companies. Created in 2003, this company presently has shareholdings in Enantia, Genmedica Therapeutics, Biocontrol Technologies, Neurotech Pharma, ImmunNovative Developments, Iproteos, Advanced Nanotechnologies, Smalle Technologies, Dapcom-Data Services and Endoasic Technologies. The ultimate objective of CIC-UB is to facilitate the creation of technology based companies obtaining economic and social return for the UB Group and society as well as the creation of highly skilled jobs.
The FBG is the center of transfer of knowledge, technology and innovation of the UB Group. Request between 22 and 25 patents per year and create between 2 and 5 technology companies a year. The FBG is the technological springboard of the UB and has the support of ACC1Ó, the Agency of the Generalitat of Catalonia, which boosts the competitiveness of the Catalan companies.
